Elanco Animal Health Incorporated (ELAN) Cash Flow Statement

The OCF/NI ratio is highly erratic, ranging from 21.55 to -22.12 over the past ten quarters, reflecting the impact of large non-cash items like amortization and volatile working capital movements. In Q2 2026, OCF of $277M against net income of $54M suggests strong cash generation relative to GAAP earnings, but the negative ratios in other quarters highlight that net income is not a reliable indicator of cash flow. Investors should focus on operating cash flow as the primary measure of underlying performance, as the gap between net income and OCF is driven by substantial D&A and working capital swings.

The FCF trajectory shows a clear improvement from the negative prints in Q1 2025 and Q1 2026, with Q2 2026 delivering the highest FCF margin (17.8%) in the ten-quarter window. This aligns with the prior income statement analysis indicating accelerating revenue growth and margin expansion. However, the volatility in FCF, driven by working capital swings, warrants caution; the company must demonstrate consistent FCF generation above its capex requirements to support deleveraging.

CapEx/Rev has ranged from 2.0% to 8.1%, with the higher figures in Q3 2025 likely reflecting investment in manufacturing capacity for new product launches. The modest capital intensity relative to peers like Zoetis (which has higher capex) suggests that ELAN's growth is more dependent on commercial execution than heavy capital outlays. This supports the view that FCF generation can be sustained as revenue grows, provided working capital is managed effectively.

The large negative working capital changes in Q1 2025, Q3 2025, and Q1 2026 suggest aggressive inventory builds or receivable collections, while positive changes in Q4 2025 and Q2 2026 indicate releases. This volatility is a key driver of the erratic OCF and FCF figures, and it may reflect channel loading or seasonal patterns. Investors should monitor inventory and receivable days to assess whether these swings are operational or indicative of demand manipulation.

The absence of dividends and negligible buybacks, combined with net cash outflows for acquisitions, suggests that management is channeling cash toward deleveraging and funding growth initiatives. The $76M acquisition outflow in Q2 2026 may reflect bolt-on acquisitions to bolster the innovation pipeline. This conservative deployment is consistent with the strained balance sheet and negative ROE, and it implies that shareholders will rely on capital appreciation rather than income.

The cumulative OCF of $1.39B versus net income of $217M underscores the significant non-cash charges, primarily amortization from the Bayer acquisition, that depress GAAP earnings. This divergence suggests that the market's focus on GAAP losses may be misplaced, as the company is generating substantial cash to service debt and fund operations. However, the negative net income in several quarters indicates that the company is not yet profitable on a GAAP basis, and the sustainability of this cash generation depends on maintaining revenue growth and controlling working capital swings.